Liposomal formulations of tacrolimus and rapamycin increase graft survival and fiber outgrowth of dopaminergic grafts.
The immunosuppressive drugs tacrolimus (TAC) and rapamycin (RAPA) have both been found to have neuroprotective effects on dopaminergic neurons. The purpose of the present study was to investigate whether liposomal formulations of these drugs administered directly into the brain improve cell survival and fiber outgrowth. Rats with unilateral 6-hydroxydopamine lesions were transplanted with 800,000 fetal rat ventral mesencephalic cells and randomly divided to one of four groups. Group 1 received a transplant containing cells only; group 2 received a cell suspension containing 0.68 microM liposomal RAPA (LRAPA); group 3 received a cell suspension containing 2.0 microM liposomal TAC (LTAC); and group 4 received a cell suspension containing a liposomal formulation of both 0.68 microM RAPA and 2.0 microM TAC (LRAPATAC). Rats were sacrificed after 6 weeks, and cell survival and fiber outgrowth were assessed using tyrosine hydroxylase (TH) immunohistochemistry. The animals receiving a cell suspension containing either LTAC or LRAPATAC were found to have significantly more surviving TH-immunoreactive (TH-ir) cells than the control group receiving cells only. The group receiving LTAC had significantly longer fibers, the group receiving LRAPA had significantly more fibers close to the graft, and the group receiving LRAPATAC had significantly more fibers at all distances. This study shows the feasibility of using liposomal formulations of neuroimmunophilins directly in the brain at the time of implantation to improve graft survival and fiber outgrowth. Furthermore, we have shown that the combination of LTAC and LRAPA has a synergistic effect. These compounds may play an important role in optimizing graft survival and host reinnervation in cell-mediated brain repair strategies for the treatment of neurological conditions.
Alemdar
Aylin Y
AY
Department of Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7.
Sadi
Damaso
D
McAlister
Vivian C
VC
Mendez
Ivar
I
D018663:Adrenergic Agents / Q000494:pharmacology; D000818:Animals; D001921:Brain / Q000473:pathology; D048708:Cell Growth Processes; D002470:Cell Survival; D017690:Cell Transplantation / Q000379:methods*; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008081:Liposomes / Q000378:metabolism*; D008636:Mesencephalon / Q000378:metabolism; D009474:Neurons / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology; D016627:Oxidopamine / Q000378:metabolism / Q000494:pharmacology; D010300:Parkinson Disease / Q000628:therapy; D051381:Rats; D017208:Rats, Wistar; D020123:Sirolimus / Q000008:administration & dosage* / Q000494:pharmacology*; D016559:Tacrolimus / Q000008:administration & dosage* / Q000494:pharmacology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D014867:Water / Q000737:chemistry
D018663:Adrenergic Agents; D007166:Immunosuppressive Agents; D008081:Liposomes; D018696:Neuroprotective Agents; D014867:Water; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine; D020123:Sirolimus; D016559:Tacrolimus